The review presented here lays out the present state of the art in the field of radionuclide
therapies specifically targeted against the nucleus of cancer cells, focussing on the use of …

Radiopharmaceutical therapy (RPT) has grown rapidly over the last decade for treatment of
numerous cancer types. Dosimetric guidance, as with other radiotherapy modalities, has …

Cancer is a leading cause of morbidity and mortality in the modern world. Treatment
modalities comprise radiation therapy, surgery, chemotherapy and hormonal therapy …

Targeted Radionuclide Therapies (TRTs) based on Auger emitting radionuclides have the
potential to deliver extremely selective therapeutic payloads on the cellular level. However …

Thulium-167 is a promising radionuclide for nuclear medicine applications with potential use
for both diagnosis and therapy (“theragnostics”) in disseminated tumor cells and small …

Abstract Antimony‐119 (119Sb) holds promise for radiopharmaceutical therapy (RPT),
emitting short‐range Auger and conversion electrons that can deliver cytotoxic radiation on …

Background Radiopharmaceutical therapy (RPT) uses radionuclides that decay via one of
three therapeutically relevant decay modes (alpha, beta, and internal conversion (IC)/Auger …

The use of Auger electrons in radionuclide therapy of cancer is a promising tool for specific
tumor cell killing of micrometastases and small tumors. The radioisotope 119Sb has recently …

Only very few radionuclides exist that decay exclusively by EC-mode without accompanying
radiation, 119Sb is one of them. Auger emitter 119Sb (T1/2= 38.9 h, IEC= 100%) is a potent …

Radionuclides find widespread use in medical technologies for treating and diagnosing
disease. Among successful and emerging radiotherapeutics, 119Sb has unique potential in …